1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 16, 24/Apr/2025
  4. Article
Outbreaks Open Access
Like 0
Download

2025 theme: Vaccines

Abstract

In November 2023, a cluster of two invasive meningococcal disease (IMD) cases caused by serogroup B (MenB) occurred in elderly residents (≥ 70 years) of a dementia care home in England. An epidemiological investigation was conducted and public health actions, including infection control measures and antibiotic chemoprophylaxis, were implemented to prevent further cases. Nasopharyngeal swabbing before chemoprophylaxis identified three meningococcal carriers, including two carrying the outbreak strain, highlighting the importance of immediate antibiotic prophylaxis in such settings. Microbiological investigations showed that the outbreak strain belonged to the sequence type (ST)-9316 complex, potentially covered by the 4CMenB vaccine. Although 4CMenB is licensed for children and adults, there are no safety or reactogenicity data on use in older adults (≥ 65 years). Given the severity of IMD, residents (64–95 years) and staff (18–72 years) were offered 4CMenB for longer-term protection, with daily diary cards to monitor side effects. In total, 30 residents and 35 of 47 staff received the first dose, with completed diary cards for 26 residents and 32 staff. Twenty-six residents and 28 staff received the second dose, and all completed diary cards. Elderly residents reported fewer and less severe side effects after each dose than younger staff.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.16.2400673
2025-04-24
2025-04-26
/content/10.2807/1560-7917.ES.2025.30.16.2400673
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/16/eurosurv-30-16-3.html?itemId=/content/10.2807/1560-7917.ES.2025.30.16.2400673&mimeType=html&fmt=ahah

References

  1. Nguyen N, Ashong D. Neisseria meningitidis. 2022 Sep 26. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31751039.
  2. Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483-98.  https://doi.org/10.1016/j.jinf.2020.05.079  PMID: 32504737 
  3. European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease. Annual epidemiological report for 2022. Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/en/publications-data/invasive-meningococcal-disease-annual-epidemiological-report-2022
  4. Clark SA, Campbell H, Ribeiro S, Bertran M, Walsh L, Walker A, et al. Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England. J Infect. 2023;87(5):385-91.  https://doi.org/10.1016/j.jinf.2023.09.002  PMID: 37689395 
  5. Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Bai X, et al. Impact of an adolescent meningococcal ACWY immunisation programme to control a national outbreak of group W meningococcal disease in England: a national surveillance and modelling study. Lancet Child Adolesc Health. 2022;6(2):96-105.  https://doi.org/10.1016/S2352-4642(21)00335-7  PMID: 34883094 
  6. European Centre for Disease Prevention and Control (ECDC). Invasive meningococcal disease. In: ECDC. Annual epidemiological report for 2021. Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/en/publications-data/invasive-meningococcal-disease-annual-epidemiological-report-2021
  7. United Kingdom Health Security Agency (UKHSA). Invasive meningococcal disease in England: annual laboratory confirmed reports for epidemiological year 2023 to 2024. London: GOV.UK; 2024. Available from: https://www.gov.uk/government/publications/meningococcal-disease-laboratory-confirmed-cases-in-england-2023-to-2024/invasive-meningococcal-disease-in-england-annual-laboratory-confirmed-reports-for-epidemiological-year-2023-to-2024
  8. Davison KL, Andrews N, White JM, Ramsay ME, Crowcroft NS, Rushdy AA, et al. Clusters of meningococcal disease in school and preschool settings in England and Wales: what is the risk? Arch Dis Child. 2004;89(3):256-60.  https://doi.org/10.1136/adc.2003.031369  PMID: 14977705 
  9. Campbell H, Parikh S, Ramsay M, Ladhani S. Guidance for public health management of meningococcal disease in the UK. London: UK Health Security Agency; 2019. Available from: https://assets.publishing.service.gov.uk/media/673257250a2b4132b43d1448/UKHSA-meningo-disease-guidelines-november2024.pdf
  10. Lawler J, Lucidarme J, Parikh S, Smith L, Campbell H, Borrow R, et al. Suspected cluster of Neisseria meningitidis W invasive disease in an elderly care home: do new laboratory methods aid public health action? United Kingdom, 2015. Euro Surveill. 2019;24(23):1900070.  https://doi.org/10.2807/1560-7917.ES.2019.24.23.1900070  PMID: 31186079 
  11. Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol. 2006;55(Pt 7):887-96.  https://doi.org/10.1099/jmm.0.46288-0  PMID: 16772416 
  12. Hill DM, Lucidarme J, Gray SJ, Newbold LS, Ure R, Brehony C, et al. Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study. Lancet Infect Dis. 2015;15(12):1420-8.  https://doi.org/10.1016/S1473-3099(15)00267-4  PMID: 26515523 
  13. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA. 2010;107(45):19490-5.  https://doi.org/10.1073/pnas.1013758107  PMID: 20962280 
  14. Bratcher HB, Corton C, Jolley KA, Parkhill J, Maiden MC. A gene-by-gene population genomics platform: de novo assembly, annotation and genealogical analysis of 108 representative Neisseria meningitidis genomes. BMC Genomics. 2014;15(1):1138.  https://doi.org/10.1186/1471-2164-15-1138  PMID: 25523208 
  15. Huson DH, Bryant D. Application of phylogenetic networks in evolutionary studies. Mol Biol Evol. 2006;23(2):254-67.  https://doi.org/10.1093/molbev/msj030  PMID: 16221896 
  16. Salomon A, Berry I, Tuite AR, Drews S, Hatchette T, Jamieson F, et al. Influenza increases invasive meningococcal disease risk in temperate countries. Clin Microbiol Infect. 2020;26(9):1257.e1-7.  https://doi.org/10.1016/j.cmi.2020.01.004  PMID: 31935565 
  17. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res. 2018;3:124.  https://doi.org/10.12688/wellcomeopenres.14826.1  PMID: 30345391 
  18. McNamara LA, MacNeil JR, Cohn AC, Stephens DS. Mass chemoprophylaxis for control of outbreaks of meningococcal disease. Lancet Infect Dis. 2018;18(9):e272-81.  https://doi.org/10.1016/S1473-3099(18)30124-5  PMID: 29858150 
  19. Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine. 2019;37(21):2768-82.  https://doi.org/10.1016/j.vaccine.2019.04.020  PMID: 30987851 
  20. Abitbol V, Martinón-Torres F, Taha MK, Nolan T, Muzzi A, Bambini S, et al. 4CMenB journey to the 10-year anniversary and beyond. Hum Vaccin Immunother. 2024;20(1):2357924.  https://doi.org/10.1080/21645515.2024.2357924  PMID: 38976659 
  21. Fernández-Prada M, Martínez-Ortega C, Hidalgo-Peña L, Álvarez-Vázquez C, Aguirre-Del Pino R, Huerta-González I. Adverse reactions associated with meningococcal group B vaccine (4CMenB) in adults in special situations. Farm Hosp. 2018;42(5):191-6. PMID: 30173636 
  22. Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18(3):483-6.  https://doi.org/10.1128/CVI.00304-10  PMID: 21177912 
  23. Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Miller E, et al. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015;33(29):3322-30.  https://doi.org/10.1016/j.vaccine.2015.05.027  PMID: 26025807 
  24. Toneatto D, Ismaili S, Ypma E, Vienken K, Oster P, Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin. 2011;7(6):646-53.  https://doi.org/10.4161/hv.7.6.15482  PMID: 21904120 
  25. Stefanizzi P, Bianchi FP, Spinelli G, Amoruso F, Ancona D, Stella P, et al. Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19. Hum Vaccin Immunother. 2022;18(1):1-6.  https://doi.org/10.1080/21645515.2021.2011652  PMID: 34435938 
  26. Perez-Vilar S, Dores GM, Marquez PL, Ng CS, Cano MV, Rastogi A, et al. Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018. Vaccine. 2022;40(2):247-54.  https://doi.org/10.1016/j.vaccine.2021.11.071  PMID: 34887130 
  27. Mentzer D, Oberle D, Keller-Stanislawski B. Adverse events following immunisation with a meningococcal serogroup B vaccine: report from post-marketing surveillance, Germany, 2013 to 2016. Euro Surveill. 2018;23(17):17-00468.  https://doi.org/10.2807/1560-7917.ES.2018.23.17.17-00468  PMID: 29717697 
  28. Marshall GS, Abbing-Karahagopian V, Marshall HS, Cenci S, Conway JH, Occhipinti E, et al. A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB). Expert Rev Vaccines. 2023;22(1):530-44.  https://doi.org/10.1080/14760584.2023.2222015  PMID: 37278390 
  29. Azevedo M, Mullis L, Agnihothram S. Viral and bacterial co-infection and its implications. SciFed Virol Res J. 2017;1(1):10.23959/sfjv-1000002.  https://doi.org/10.23959/sfjv-1000002  PMID: 29974891 
  30. United Kingdom Health Security Agency (UKHSA). Guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza. London: UKHSA; 2021. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058443/ukhsa-guidance-antivirals-influenza-11v4.pdf
  31. Deghmane AE, Haeghebaert S, Hong E, Jousset A, Barret AS, Taha MK. Emergence of new genetic lineage, ST-9316, of Neisseria meningitidis group W in Hauts-de-France region, France 2013-2018. J Infect. 2020;80(5):519-26.  https://doi.org/10.1016/j.jinf.2020.01.020  PMID: 32032620 
  32. Muzzi A, Brozzi A, Serino L, Bodini M, Abad R, Caugant D, et al. Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019;37(7):991-1000.  https://doi.org/10.1016/j.vaccine.2018.12.061  PMID: 30661831 
  33. Hill DM, Lucidarme J, Gray SJ, Newbold LS, Ure R, Brehony C, et al. Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study. Lancet Infect Dis. 2015;15(12):1420-8.  https://doi.org/10.1016/S1473-3099(15)00267-4  PMID: 26515523 
Use of 4CMenB vaccine in the control of an outbreak of serogroup B invasive meningococcal disease in an elderly care home, England, November 2023
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Emma+J+Heymer&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Heymer Emma J</a>, <a href="/search?value1=Stephen+A+Clark&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Clark Stephen A</a>, <a href="/search?value1=Helen+Campbell&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Campbell Helen</a>, <a href="/search?value1=Sonia+Ribeiro&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ribeiro Sonia</a>, <a href="/search?value1=Lloyd+Walsh&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Walsh Lloyd</a>, <a href="/search?value1=Jay+Lucidarme&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lucidarme Jay</a>, <a href="/search?value1=Xilian+Bai&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Bai Xilian</a>, <a href="/search?value1=Tom+Irving&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Irving Tom</a>, <a href="/search?value1=Anna+Hoad&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Hoad Anna</a>, <a href="/search?value1=Jaime+Morgan&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Morgan Jaime</a>, <a href="/search?value1=Ray+Borrow&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Borrow Ray</a>, <a href="/search?value1=Shamez+N+Ladhani&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ladhani Shamez N</a></span>. Use of 4CMenB vaccine in the control of an outbreak of serogroup B invasive meningococcal disease in an elderly care home, England, November 2023. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(16):pii=2400673. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.16.2400673" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.16.2400673</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 07 Oct 2024;&nbsp;&nbsp; <span class="generated">Accepted</span>: 13 Jan 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.16.2400673
/content/10.2807/1560-7917.ES.2025.30.16.2400673
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error